| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
BALTIMORE—Privately held biopharma Gliknik Inc. announcedSept. 30 that it had entered into an exclusive worldwide licensing agreementwith Pfizer Inc. for GL-2045, Gliknik's recombinant stradomer, a drug candidatethat is designed to replace and improve on pooled human intravenousimmunoglobulin (IVIG). GL-2045 reportedly has shown promising results in abroad range of preclinical tests and is being developed as a potentialtreatment for a variety of autoimmune diseases, including those in which IVIGis clinically used.
 
 
Under the terms of the license agreement, Pfizerwill receive an exclusive worldwide license to GL-2045 for all therapeuticindications. In return, Gliknik will receive an upfront payment of $25 millionand is eligible to receive development, regulatory and commercial milestonepayments. Gliknik is also eligible to receive tiered, double-digit royalties onnet sales of any products that are commercialized pursuant to this licenseagreement.
 
 
"People with certain autoimmune diseases havelimited treatment options, difficult regimens and often a poor prognosis,"said Dr. Jose Carlos Gutierrez-Ramos, group senior vice president and head of biotherapeuticsR&D at Pfizer. "Pooled IVIG has a long history of use but has a numberof limitations. We are pleased to partner with Gliknik on this noveltherapeutic approach which may provide an important new option in managing debilitatingautoimmune diseases."
 
 
"GL-2045 is the first of several innovativedrug candidates Gliknik is advancing for people with autoimmune diseases andcancer," said David S. Block, CEO of Gliknik. "We selected Pfizer asour partner to progress GL-2045 from among several interested and capableparties because of its exceptional development, manufacturing and commercialcapabilities." 

SOURCE: Gliknik news release


About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue